Minghui Pharmaceutical is a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address unmet medical needs in oncology and autoimmune diseases. With expertise in medical science and proprietary technology platforms, the company has built a diverse clinical-stage pipeline, including novel ADC programs and a PD-1xVEGF bispecific antibody. Minghui is committed to advancing breakthrough therapies that improve patient outcomes worldwide.

Sanyou Biopharmaceuticals is a cutting-edge antibody drug discovery and development company, featured by its super-trillion antibody library and its capability of both AI and wet-lab R&D platforms, with the mission of “making innovative biologics R&D easy for clients worldwide.”

Focusing on its intelligent super-trillion antibody library, Sanyou has built a world-leading, integrated and intelligent R&D platform for preclinical development of innovative biologics that seamlessly combines in silico and wet-lab capabilities. The company accelerates global new drug discovery and target research through four dimensions: new drug discovery, preclinical research, AI-driven drug development, and frontier scientific research.

Headquartered in Shanghai, China, Sanyou has subsidiaries in the United States, Europe, and other regions, with over 20,000 square meters of R&D and GMP-compliant facilities in operation or under development.

Sanyou offers its clients and partners a comprehensive "4C" service solution set that includes CRO, CDO, CPO (Collaborative Project Organization), and CRS (Core Reagent Solution) services. The company has established a global marketing network and formed strong partnerships with more than 1,200 pharmaceutical and biotech companies worldwide. It has successfully completed over 1,200 projects related to new drug discovery and development, more than 50 collaborative R&D projects, with 9 projects having completed IND submission.

Sanyou has been recognized as a National High-tech Enterprise, a Shanghai "Specialized and Innovative" Enterprise, a Shanghai "Little Giant" Enterprise, and a "Zhangjiang Star" Enterprise in Shanghai.